These analyses revealed activation of mitogen-activated protein kinase p38α/β, and NF-κB subunit p65/RelA in the NSCLC cells that are resistant to Erlotinib or Rociletinib (Supplementary Figure 3A). This evidence concerns the gene NFKB1 and non-small cell lung carcinoma.